Itrasys 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections caused by susceptible strains, including aspergillosis, blastomycosis, histoplasmosis, and onychomycosis. Itraconazole exerts its antifungal effect by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrasys 200 Capsule is administered orally and is well-absorbed when taken with food, ensuring optimal bioavailability. The dosage and duration of therapy depend on the type and severity of the infection, as well as patient response. Caution is advised in patients with hepatic impairment, congestive heart failure, or those taking concomitant medications metabolized by the cytochrome P450 system due to potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Itrasys 200 Capsule should be used under medical supervision to ensure safety and efficacy in managing fungal infections.